SCHEMBL6324704

SCHEMBL6324704

Cc1ccc(-c2noc(N)c2C(=O)NCC2CCCO2)o1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 7/20 0.60
L3MBTL1 Q9Y468 3/20 0.60
ALDH1A1 P00352 3/20 0.53
TSHR P16473 2/20 0.53
HPGD P15428 8/20 0.52
RAB9A P51151 5/20 0.52
NPC1 O15118 5/20 0.52
ATM Q13315 2/20 0.52
TP53 P04637 1/20 0.52
KMT2A Q03164 3/20 0.51
MEN1 O00255 1/20 0.51
MCL1 Q07820 1/20 0.51
HIF1A Q16665 1/20 0.51
LMNA P02545 2/20 0.48
MAPT P10636 4/20 0.47
POLB P06746 3/20 0.47
CYP1A2 P05177 1/20 0.47
CYP2C9 P11712 1/20 0.47
CYP2C19 P33261 1/20 0.47
KDM4E B2RXH2 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6322807 0.87 NPSR1 (0.44) SMN1; SMN2L3MBTL1ALDH1A1TSHRHIF1A
SCHEMBL6318857 0.86 NPSR1 (0.42) SMN1; SMN2L3MBTL1ALDH1A1HPGDRAB9A
SCHEMBL6318036 0.83 HPGD (0.55) SMN1; SMN2L3MBTL1ALDH1A1TSHRHPGD
SCHEMBL6320752 0.81 HIF1A (0.52) SMN1; SMN2L3MBTL1ALDH1A1TSHRHPGD
SCHEMBL6318810 0.81 RAB9A (0.52) SMN1; SMN2L3MBTL1ALDH1A1TSHRHPGD
SCHEMBL6320687 0.80 SMN1; SMN2 (0.48) SMN1; SMN2ALDH1A1TSHRHPGDRAB9A
SCHEMBL6316428 0.80 SMN1; SMN2 (0.51) SMN1; SMN2ALDH1A1TSHRHPGDRAB9A
SCHEMBL6321764 0.79 SMN1; SMN2 (0.53) SMN1; SMN2ALDH1A1TSHRHPGDRAB9A
SCHEMBL6316098 0.79 SMN1; SMN2 (0.53) SMN1; SMN2ALDH1A1TSHRHPGDRAB9A
SCHEMBL6314998 0.79 MAPT (0.44) ALDH1A1TSHRMAPTPOLBHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US claimed
CN-1549714-A Aminoisoxazole derivatives active as kinase inhibitors 2004-11-24 CN claimed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP claimed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO claimed
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US disclosed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP disclosed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors MAP3K9, MAP3K19, MAP4K2 SMN1; SMN2 2766/4885L3MBTL1 4176/4885ALDH1A1 4444/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.